Protein-tyrosine phosphatase inhibitors block tumor necrosis factor-dependent activation of the nuclear transcription factor NF-kappa B.
Most of the inflammatory and proviral effects of tumor necrosis factor (TNF) are mediated through the activation of the nuclear transcription factor NF-kappa B. How TNF activates NF-kappa B, however, is not well understood. We examined the role of protein phosphatases in the TNF-dependent activation of NF-kappa B. Treatment of human myeloid ML-1a cells with TNF rapidly activated (within 30 min) NF-kappa B; this effect was abolished by treating cells with inhibitors of protein-tyrosine phosphatase (PTPase), including phenylarsine oxide (PAO), pervanadate, and diamide. The inhibition was dependent on the dose and occurred whether added before or at the same time as TNF. PAO also inhibited the activation even when added 15 min after the TNF treatment of cells. In contrast to inhibitors of PTPase, okadaic acid and calyculin A, which block serine-threonine phosphatase, had no effect. The effect of PTPase inhibitors was not due to the modulation of TNF receptors. Since both dithiothreitol and dimercaptopropanol reversed the inhibitory effect of PAO, critical sulfhydryl groups in the PTPase must be involved in NF-kappa B activation by TNF. PTPase inhibitors also blocked NF-kappa B activation induced by phorbol ester, ceramide, and interleukin-1 but not that activated by okadaic acid. The degradation of I kappa B protein, a critical step in NF-kappa B activation, was also abolished by the PTPase inhibitors as revealed by immunoblotting. Thus, overall, we demonstrate that PTPase is involved either directly or indirectly in the pathway leading to the activation of NF-kappa B.
Singh
S
S
Department of Clinical Immunology and Biological Therapy, University of Texas M. D. Anderson Cancer Center, Houston 77030.
Aggarwal
B B
BB
D000255:Adenosine Triphosphate / Q000378:metabolism; D001152:Arsenicals / Q000494:pharmacology; D001483:Base Sequence; D002518:Ceramides / Q000494:pharmacology; D004268:DNA-Binding Proteins / Q000378:metabolism; D003958:Diamide / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004988:Ethers, Cyclic / Q000494:pharmacology; D006801:Humans; D020672:I-kappa B Proteins; D066298:In Vitro Techniques; D007375:Interleukin-1 / Q000494:pharmacology; D008387:Marine Toxins; D008969:Molecular Sequence Data; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism*; D019319:Okadaic Acid; D009838:Oligodeoxyribonucleotides / Q000737:chemistry / Q000378:metabolism; D010080:Oxazoles / Q000494:pharmacology; D017027:Protein Tyrosine Phosphatases / Q000037:antagonists & inhibitors*; D015398:Signal Transduction; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D013997:Time Factors; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*; D014638:Vanadates / Q000494:pharmacology
D001152:Arsenicals; D002518:Ceramides; D004268:DNA-Binding Proteins; D004988:Ethers, Cyclic; D020672:I-kappa B Proteins; D007375:Interleukin-1; D008387:Marine Toxins; D016328:NF-kappa B; C000606204:NFKBIA protein, human; D009838:Oligodeoxyribonucleotides; D010080:Oxazoles; D014409:Tumor Necrosis Factor-alpha; C076715:pervanadate; C029341:oxophenylarsine; D003958:Diamide; D000072000:NF-KappaB Inhibitor alpha; D019319:Okadaic Acid; D014638:Vanadates; C059041:calyculin A; D000255:Adenosine Triphosphate; D017027:Protein Tyrosine Phosphatases; D013755:Tetradecanoylphorbol Acetate